BridgeBio Oncology Therapeutics, Inc. BBOT 深 滬
等待開盤 09-18 09:30:00 美东时间
4.89
+0.130
+2.73%
華盛通- 最 高5.10
- 今 開4.84
- 成交量 41.74万股
- 最 低 4.84
- 昨 收 4.76
- 總市值 3.92亿
- 52周最高 14.87
- 市盈率 靜 --
- 換手率 0.52%
- 52周最低 4.71
- 委 比 -77.33%
- 總股本 8017.43万
- 歷史最高 14.87
- 量 比 0.30
- 振 幅 5.46%
- 歷史最低 4.71
- 每 手 1
- 風險率 1.87%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 齐声看好医药股！礼来、强生、默沙东目标价均获上调；小摩大幅上调Meta目标价至820美元
今日重点评级关注：康托·菲茨杰拉德：维持SOL Strategies"超配"评级，目标价从2.8美元升至6.2美元；康托·菲茨杰拉德：维持Sui Group Holdings"超配"评级，目标价从1.7美元升至3.4美元
09-11 14:30
美股大行评级 | 戴尔、Adobe获大行上调目标价；甲骨文绩前目标价遭调低
今日重点评级关注：富国银行：维持Pyxis Oncology"超配"评级，目标价从12美元升至19美元；Oppenheimer：维持Opus Genetics"跑赢大市"评级，目标价从10美元升至20美元
09-10 15:00
Wedbush Reiterates Outperform on BridgeBio Oncology, Maintains $25 Price Target
Wedbush analyst David Nierengarten reiterates BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and maintains $25 price target.
09-09 20:21
Bridgebio Announces New KRASG12C Data And Strategic Prioritization Of BBO-8520 In Combination With Checkpoint Inhibitor In 2L+ KRASG12C Inhibitor-Experienced NSCLC Patients And BBO-11818 And BBO-10203 In KRAS-Mutant Cancers
BBO-8520 plus pembrolizumab demonstrated a 75% ORR at 500 mg QD and 53% ORR across dose levels in 2L+ KRASG12C inhibitor-experienced NSCLC patients BBO-8520 monotherapy continues to show highly competitive ORR in the 2L+ KRASG12C inhibitor-naïve NSCLC with ORR of 63% (26/41), disease control rate (D...
09-09 04:08
美股大行评级 | 富国上调闪迪目标价从1400美元升至1550美元；塔吉特、Workday、应用材料等获多家大行上调目标价
今日重点评级关注：富瑞：维持ProMIS Neurosciences"买入"评级，目标价从69美元升至100美元；Benchmark：维持Cineverse"买入"评级，目标价从12美元升至14美元
08-17 13:37
JP Morgan Maintains Overweight on BridgeBio Oncology, Lowers Price Target to $25
JP Morgan analyst Priyanka Grover maintains BridgeBio Oncology (NASDAQ:BBOT) with a Overweight and lowers the price target from $27 to $25.
08-15 00:16
BridgeBio Oncology Q2 EPS $(705.20) Misses $(0.57) Estimate
BridgeBio Oncology (NASDAQ:BBOT) reported quarterly losses of $(705.20) per share which missed the analyst consensus estimate of $(0.57) by 123619.3 percent. This is a 24.49 percent decrease over losses of $(566.46) per share from the same period last year.
08-12 04:39
美股大行评级 | 潜在涨幅215.37%！摩根士丹利上调TeraWulf(WULF)目标价至72美元，维持"超配"评级
今日重点评级关注：摩根士丹利：维持TeraWulf"超配"评级，目标价从66.5美元升至72美元；HC Wainwright & Co.：维持Vera Therapeutics"买入"评级，目标价从110美元升至125美元
07-09 12:35
JP Morgan Initiates Coverage On BridgeBio Oncology with Overweight Rating, Announces Price Target of $27
JP Morgan analyst Priyanka Grover initiates coverage on BridgeBio Oncology (NASDAQ:BBOT) with a Overweight rating and announces Price Target of $27.
07-08 18:09
美股大行评级 | 阿斯麦获美银、富国上调目标价最高至2345美元；Needham上调美光科技目标价从500美元升至1550美元
今日重点评级关注：Baird：维持Regenxbio"跑赢大市"评级，目标价从27美元升至32美元；古根海姆：维持Tenax Therapeutics"买入"评级，目标价从34美元升至40美元
06-23 13:48
